Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04018872 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
A Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagus Adenocarcinoma, sponsored by Dallas VA Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT04018872 is a Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagus Adenocarcinoma that is actively recruiting participants, run by Dallas VA Medical Center. The registered enrollment target is 78 participants, below the 402-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04018872, a Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagus Adenocarcinoma, is actively recruiting participants, sponsored by Dallas VA Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following standard of care chemoradiation in the treatment of locoregional esophageal and gastroesophageal junction carcinomas.
Conditions Studied
Interventions
- DRUG Itraconazole
Study Locations (1)
Texas
- Dallas VA Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2026-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04018872
The ClinicalTrials.gov registry entry for NCT04018872 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 402-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (81% lower). The listed sponsor is Dallas VA Medical Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Itraconazole is the first listed.
NCT04018872 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04018872 about?
NCT04018872 is a clinical study titled "Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer". Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal ...
What is the current status of trial NCT04018872?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2019-06-24. Estimated completion is 2026-09-29.
What conditions does trial NCT04018872 study?
This clinical trial studies the following conditions: Gastroesophageal Junction Adenocarcinoma, Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04018872?
The interventions under investigation include: Itraconazole (DRUG).
Who is sponsoring clinical trial NCT04018872?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04018872 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
Folfox+Irinotecan+Chemort In Esophageal Cancer
RECRUITING · Phase 2
-
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.